Trial · NCT00784654
Adverse events129
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 129
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Decreased appetite | Metabolism and nutrition disorders | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 76 | 276 | 91 |
| other | Decreased appetite | Metabolism and nutrition disorders | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 3 | 78 | 3 |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo (Randomized Period) | 0 | 79 | 0 |
| other | Headache | Nervous system disorders | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 58 | 276 | 80 |
| other | Headache | Nervous system disorders | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 6 | 78 | 6 |
| other | Headache | Nervous system disorders | Placebo (Randomized Period) | 5 | 79 | 7 |
| other | Weight decreased | Investigations | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 46 | 276 | 60 |
| other | Weight decreased | Investigations | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 2 | 78 | 2 |
| other | Weight decreased | Investigations | Placebo (Randomized Period) | 1 | 79 | 1 |
| other | Nasopharyngitis | Infections and infestations | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 43 | 276 | 64 |
| other | Nasopharyngitis | Infections and infestations | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 7 | 78 | 7 |
| other | Nasopharyngitis | Infections and infestations | Placebo (Randomized Period) | 3 | 79 | 3 |
| other | Anorexia | Metabolism and nutrition disorders | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 41 | 276 | 48 |
| other | Anorexia | Metabolism and nutrition disorders | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 0 | 78 | 0 |
| other | Anorexia | Metabolism and nutrition disorders | Placebo (Randomized Period) | 0 | 79 | 0 |
| other | Insomnia | Psychiatric disorders | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 39 | 276 | 44 |
| other | Insomnia | Psychiatric disorders | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 1 | 78 | 1 |
| other | Insomnia | Psychiatric disorders | Placebo (Randomized Period) | 1 | 79 | 1 |
| other | Vomiting | Gastrointestinal disorders | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | 32 | 276 | 43 |
| other | Vomiting | Gastrointestinal disorders | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 2 | 78 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00784654/events